Johnson & Johnson (NYSE:JNJ) Shares Sold by MidWestOne Financial Group Inc.

MidWestOne Financial Group Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,948 shares of the company’s stock after selling 151 shares during the quarter. MidWestOne Financial Group Inc.’s holdings in Johnson & Johnson were worth $3,319,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Sulzberger Capital Advisors Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth $453,000. Oregon Pacific Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $949,000. Horan Securities Inc. grew its stake in shares of Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after buying an additional 90 shares in the last quarter. Strategic Financial Concepts LLC raised its holdings in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after buying an additional 1,271 shares during the period. Finally, State of Wyoming boosted its holdings in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after acquiring an additional 10,279 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.7%

Shares of NYSE:JNJ opened at $153.58 on Wednesday. The company’s fifty day moving average is $155.87 and its two-hundred day moving average is $153.80. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The stock has a market capitalization of $369.52 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent research reports. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Barclays dropped their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.